Bracco Diagnostics of Princeton, NJ, has been awarded a contract by group purchasing organization Amerinet.
Under terms of the agreement, Bracco's injectable contrast media products will be made available to Amerinet members via a single contract through 2008, the company said.
The contract includes Isovue (iopamidol injection); MultiHance (gadobenate dimeglumine) injection, 529 mg/mL; ProHance (gadoteridol) injection, 279.3 mg/mL; and Bracco's ionic product line.
By AuntMinnie.com staff writers
January 26, 2006
Related Reading
Bracco to sell Esaote, January 23, 2006
Esaote rolls out Picus-Just 4D ultrasound, November 11, 2005
Bracco, Toshiba partner in 64-slice CTA trial, July 13, 2005
FDA OKs expanded use for Kinevac, June 1, 2005
Consorta selects Bracco, May 26, 2005
Copyright © 2006 AuntMinnie.com
![Axial images from unenhanced calcium score cardiac CT (left) and curved planar reformation images from CT angiography (right) show that higher long-term exposure to air pollution is associated with greater coronary artery calcium and more obstructive coronary artery disease (CAD). Top row: Images in a 68-year-old male patient with higher 10-year mean ambient air pollution exposure (7.9 μg/m3 for particulate matter measuring ≤2.5 μm in diameter [PM2.5] and 17.4 parts per billion [ppb] for NO2) with extensive CAD (coronary artery calcium score [CACS] >1,000 and obstructive CAD [≥70% diameter stenosis]). Bottom row: Images in a 57-year-old female patient with lower 10-year mean ambient air pollution exposure (6.3 μg/m3 for PM2.5 and 4.6 ppb for NO2) with no CAD (CACS = 0 and no obstructive stenosis).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/06/hanneman.r6SMLzkezo.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
